Raymond James Financial Services Advisors’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $79.2K | Buy |
21,301
+4,300
| +25% | +$16K | ﹤0.01% | 3307 |
|
|
2024
Q2 | $107K | Buy |
17,001
+1,600
| +10% | +$10.1K | ﹤0.01% | 3217 |
|
|
2024
Q1 | $82.7K | Buy |
15,401
+3,195
| +26% | +$17.2K | ﹤0.01% | 3240 |
|
|
2023
Q4 | $61.3K | Buy |
12,206
+250
| +2% | +$1.26K | ﹤0.01% | 3174 |
|
|
2023
Q3 | $20.2K | Sell |
11,956
-850
| -7% | -$1.44K | ﹤0.01% | 3169 |
|
|
2023
Q2 | $35.6K | Sell |
12,806
-1,108
| -8% | -$3.08K | ﹤0.01% | 3143 |
|
|
2023
Q1 | $25.3K | Buy |
13,914
+900
| +7% | +$1.64K | ﹤0.01% | 3156 |
|
|
2022
Q4 | $66K | Sell |
13,014
-1,500
| -10% | -$7.61K | ﹤0.01% | 3054 |
|
|
2022
Q3 | $72K | Buy |
14,514
+893
| +7% | +$4.43K | ﹤0.01% | 3033 |
|
|
2022
Q2 | $51K | Buy |
+13,621
| New | +$51K | ﹤0.01% | 3068 |
|